Treatment with heavy charged particles: Systematic review of clinical data and current clinical (comparative) trials

Acta Oncologica

Volumn 52, Issue 7, 2013, Pages 1272-1286

  Combs, Stephanie E ^a   Debus, Jürgen ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOID CYSTIC CARCINOMA; CANCER SURVIVAL; CHILDHOOD CANCER; CHONDROSARCOMA; CHORDOMA; ESOPHAGUS CANCER; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HUMAN; IMMOBILIZATION; INTERMETHOD COMPARISON; ION THERAPY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; MEDLINE; MELANOMA; MENINGIOMA; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTON THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PUBLICATION; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; REVIEW; SKULL BASE TUMOR; SOFT TISSUE SARCOMA; SPINE TUMOR; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; THORAX CANCER; TREATMENT INDICATION; TREATMENT PLANNING; UTERINE CERVIX CARCINOMA; UTERUS SARCOMA; ARTICLE; BRAIN TUMOR; CANCER RADIOTHERAPY; CARBON ION RADIOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED RADIOTHERAPY; DIGESTIVE SYSTEM CANCER; FEMALE GENITAL TRACT CANCER; HEAD AND NECK TUMOR; HEALTH CARE COST; IMAGE GUIDED RADIOTHERAPY; IN VITRO STUDY; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; MUCOSAL MELANOMA; PROTON THERAPY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOBIOLOGY; RECTUM CANCER; SALIVARY GLAND TUMOR; SARCOMA;

ALGORITHMS; CLINICAL TRIALS AS TOPIC; HEAVY ION RADIOTHERAPY; HEAVY IONS; HUMANS; NEOPLASMS;

BIOLOGICAL MARKER;

EID: 84884564763     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.818254     Document Type: Review

References (111)

1. Combs SE, Ellerbrock M, Haberer T, Habermehl D, Hoess A, JakeLo, et al. Heidelberg Ion Therapy Center (HIT): Initial clinicaLexperience in the fi rst 80 patients. Acta Oncol 2010;49:1132-40
2. Combs S E, Bohl J, Elsasser T, Weber K J, Schulz-Ertner D, Debus J, et al. RadiobiologicaLevaluation and correlation with thElocaLeffect model (LEM) of carbon ion radiation therapy and temozolomide iNglioblastoma cell lines. Int J Radiat Biol 2009;85:126-37
3. Rieken S, Habermehl D, Nikoghosyan A, Jensen A, Haberer T, JakeLo, et al. Assessment of early toxicity and response in patients treated with proton and carbon ion therapy at the Heidelberg ion therapy center using the raster scanning technique. Int J Radiat Oncol Biol Phys 2011;81:e793-801
4. Tsujii H, Kamada T. A review of update clinical results of carbon ion radiotherapy. Jpn J Clin Oncol 2012;42:670-85
5. Tsujii H, Mizoe J E, Kamada T, Baba M, Kato S, KatOh, et al. Overview of clinicaLexperiences on carbon ion radiotherapy at NIRS. Radiother Oncol 2004;73(Suppl2):S41-9
6. Combs SE, Zipp L, Rieken S, Habermehl D, Brons S, Winter M, et al. In vitro evaluation of photon and carbon ion radiotherapy in combination with chemotherapy iNglioblastoma cells. Radiat Oncol 2012;7:9
7. Fujita M, Otsuka Y, Imadome K, Endo S, Yamada S, Imai T. Carbon-ion radiation enhances migration ability anDinvasiveness of the pancreatic cancer cell, PANC-1, in vitro. Cancer Sci 2012;103:677-83
8. Higo M, Uzawa K, Kawata T, Kato Y, Kouzu Y, Yamamoto N, et al. Enhancement of SPHK1 in vitro by carbon ion irradiation in oral squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2006;65:867-75
9. Rieken S, Habermehl D, Wuerth L, Brons S, Mohr A, Lindel K, et al. Carbon ion irradiation inhibits glioma cell migration through downregulation of integrin expression. Int J Radiat Oncol Biol Phys 2012;83:394-9
10. Takahashi T, Fukawa T, Hirayama R, Yoshida Y, Musha A, Furusawa Y, et al. In vitro interaction of high-LETheavyion irradiation and chemotherapeutic agents in two cell lines with different radiosensitivities and different p53 status . Anticancer Res 2010;30:1961-7
11. Becker D, Elsasser T, Tonn T, SeifrieDe, Durante M, Ritter S, et al. Response of human hematopoietic stem and progenitor cells to energetic carbon ions. Int J Radiat Biol 2009;85:1051-9
12. Oonishi K, Cui X, Hirakawa H, Fujimori A, Kamijo T, Yamada S, et al. Different effects of carbon ion beams and X-rays on clonogenic survival and DNA repair in human pancreatic cancer stem-like cells. Radiother Oncol 2012;105:258-65
13. Combs S E, Hartmann C, Nikoghosyan A, Jake L, Karger CP, Haberer T, et al. Carbon ion radiation therapy for high-risk meningiomas. Radiother Oncol 2010;95:54-9
14. Combs S E, Nikoghosyan A, JaekeLo, Karger C P, Haberer T, Munter MW, et al. Carbon ion radiotherapy for pediatric patients and young adults treated for tumors of the skull base. Cancer 2009;115:1348-55
15. Debus J, Haberer T, Schulz-Ertner D, JakeLo, Wenz F, Enghardt W, et al. [Carbon ion irradiation of skull base tumors at GSI. First clinical results and future perspectives]. Strahlenther Onkol 2000;176:211-6
16. Nikoghosyan A V, Schulz-Ertner D, Herfarth K, Didinger B, Munter MW, Jensen AD, et al. Acute toxicity of combined photon IMRT and carbon ion boost for intermediate-risk prostate cancer-acute toxicity of 12C for PC. Acta Oncol 2011;50:784-90
17. Schlampp I, Karger C P, JakeLo, Scholz M, Didinger B, Nikoghosyan A, et al. Temporal lobe reactions after radiotherapy with carbon ions: Incidence anDestimation of the relative biologicaLeffectiveness by thElocaLeffect model. Int J Radiat Oncol Biol Phys 2011;80:815-23
18. Schulz-Ertner D, Nikoghosyan A, Hof H, Didinger B, Combs SE, JakeLo, et al. Carbon ion radiotherapy of skull base chondrosarcomas. Int J Radiat Oncol Biol Phys 2007;67:171-7
19. Schulz-Ertner D, Nikoghosyan A, Didinger B, Debus J. Carbon ion radiation therapy for chordomas and low grade chondrosarcomas-current status of the clinical trials at GSI. Radiother Oncol 2004;73(Suppl2):S53-6
20. Schulz-Ertner D, Nikoghosyan A, Thilmann C, Haberer T, JakeLo, Karger C, et al. Results of carbon ion radiotherapy in 152 patients. Int J Radiat Oncol Biol Phys 2004;58:631-40
21. Schulz-Ertner D, Nikoghosyan A, Thilmann C, Haberer T, JakeLo, Karger C, et al. Carbon ion radiotherapy for chordomas and low-grade chondrosarcomas of the skull base. Results in 67 patients. Strahlenther Onkol 2003;179:598-605
22. Schulz-Er [22] tner D, Nikoghosyan A, JakeLo, Haberer T, Kraft G, Scholz M, et al. Feasibility and toxicity of combined photon and carbon ion radiotherapy for locally advanced adenoid cystic carcinomas. Int J Radiat Oncol Biol Phys 2003;56:391-8
23. Debus J, Schulz-Ertner D, Schad L, Essig M, Rhein B, Thillmann CO, et al. Stereotactic fractionated radiotherapy for chordomas and chondrosarcomas of the skull base. Int J Radiat Oncol Biol Phys 2000;47:591-6
24. Bugoci DM, Girvigian MR, Chen JC, Miller MM, Rahimian J. Photon-based fractionated stereotactic radiotherapy for postoperative treatment of skull base chordomas. Am J Clin OncoLepub 2012 Jul 3
25. Torres M A, Chang EL, Mahajan A, Lege D G, Riley B A, Zhang X, et al. Optimal treatment planning for skull base chordoma: Photons, protons, or a combination of both? Int J Radiat Oncol Biol Phys 2009;74:1033-9
26. Mizoe JE, Tsujii H, Hasegawa A, Yanagi T, Takagi R, Kamada T, et al. Phase I/II clinical triaLof carbon ion radiotherapy for malignant gliomas: Combined x-ray radiotherapy, chemotherapy, and carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 2007;69:390-6
27. Koto M, Hasegawa A, Takagi R, et al. Carbon ion radiotherapy for skull base and paracervical tumors. Proceedings of the NIRS-ETOILE 2nd Joint Symposium on Carbon Ion Radiotherapy, 2011, Center ETOILE, Lyon, NIRS-M-243. 2011. [Abstract
28. Kamada T. O verview of the carbon ion therapy at HIMAC (including head and neck tumors, and bone and soft tissue sarcomas). Proceedings of the Joint Symposium 2013 on Carbon Ion Radiotherapy, May 2-3, 2013, Rochester, MN, USA. 2013. [Abstract
29. Mizoe JE, Hasegawa A, Takagi R, Bessho H, Onda T, Tsujii H. Carbon ion radiotherapy for skull base chordoma. Skull Base 2009;19:219-24
30. Schulz-Ertner D, Karger C P, Feuerhake A, Nikoghosyan A, Combs SE, JakeLo, et al. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys 2007;68:449-57
31. Nikoghosyan AV, Karapanagiotou-SchenkeLi, Munter MW, Jensen AD, Combs SE, Debus J. Randomised triaLof proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study. BMC Cancer 2010;10:607
32. Nikoghosyan A V, Rauch G, Munter MW, Jensen A D, Combs SE, Kieser M, et al. Randomised triaLof proton vs. carbon ion radiation therapy in patients with low and intermediate grade chondrosarcoma of the skull base, clinical phase III study. BMC Cancer 2010;10:606
33. Hasegawa A, Mizoe JE, Tsujii H, Kamada T, Jingu K, Iwadate Y, et al. Experience with carbon ion radiotherapy for WHO Grade 2 diffuse astrocytomas. Int J Radiat Oncol Biol Phys 2012;83:100-6
34. Combs S E, Kieser M, Rieken S, Habermehl D, JakeLo, Haberer T, et al. Randomized phase II studYevaluating a carbon ion boost applied after combined radiochemo therapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: The CLEOPATRA trial. BMC Cancer 2010;10:478
35. Rieken S, Habermehl D, Haberer T, JaekeLo, Debus J, Combs SE. Proton and carbon ion radiotherapy for primary brain tumors delivered witHactive raster scanning at the Heidelberg Ion Therapy Center (HIT): Early treatment results and study concepts. Radiat Oncol 2012;7:41
36. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109
37. PalmAl, Celli P, Franco C, Cervoni L, Cantore G. Longterm prognosis for atypical and malignant meningiomas: A study of 71 surgical cases. Neurosurg Focus 1997;2:e3
38. Lusis E, Gutmann DH. M eningioma: An update. Curr Opin Neurol 2004;17:687-92
39. Milker-Zabel S, Zabel A, Schulz-Ertner D, Schlegel W, Wannenmacher M, Debus J. Fractionated stereotactic radiotherapy in patients with benign or atypicaLintracranial meningioma: Long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys 2005;61:809-16
40. Simon M, Bostrom J, Koch P, Schramm J. I nterinstitutional variance of postoperative radiotherapy and folloWup for meningiomas iNgermany: Impact of changes of the WHO classification. J Neurol Neurosurg Psychiatry 2006;77:767-73
41. Engenhart-Cabillic R, Farhoud A, Sure U, Heinze S, Henzel M, Mennel HD, et al. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment. Strahlenther Onkol 2006;182:641-6
42. Hoffmann W, Muhleisen H, Hess C F, Kortmann RD, Schmidt B, Grote EH, et al. Atypical and anaplastic meningiomas-does the new WHO-classification of brain tumours affect the indication for postoperative irradiation? Acta Neurochir (Wien) 1995;135:171-8
43. Milosevic M F, Frost P J, Laperriere N J, Wong C S, Simpson WJ. Radiotherapy for atypicaLor malignant intracranial meningioma. Int J Radiat Oncol Biol Phys 1996;34:817-22
44. Hug E B, Devries A, Thornton AF, Munzenride J E, Pardo FS, Hedley-Whyte ET, et al. Management of atypical and malignant meningiomas: Role of high-dose, 3Dconformal radiation therapy. J Neurooncol 2000;48:151-60
45. Milker-Zabel S, Zabel A, Schulz-Ertner D, Schlegel W, Wannenmacher M, Debus J. Fractionated stereotactic radiotherapy in patients with benign or atypicaLintracranial meningioma: Long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys 2005;61:809-16
46. Smith SJ, Boddu S, Macarthur D C. A typical meningiomas: WHO moved the goalposts? Br J Neurosurg 2007;21:588-92
47. Pasquier D, Bijmolt S, Veninga T, Rezvoy N, Villa S, KrenglIm, et al. Atypical and malignant meningioma: Outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the rare cancer network. Int J Radiat Oncol Biol Phys 2008;71:1388-93
48. Combs S E, Welzel T, Habermehl D, Rieken S, Dittmar JO, Kessel K, et al. Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume defi nition with MRI and 68Ga-DOTATOC-PET. Acta Oncol 2013;52:514-20
49. Combs S E, Hartmann C, Nikoghosyan A, JakeLo, Karger C, von Deimling A, et al. Carbon ion radiotherapy for high-risk meningiomas. Int J Radiat Oncol Biol Phys 2009;75:399-406
50. Combs S E, Edler L, Burkholder I, Rieken S, Habermehl D, JakeLo, et al. Treatment of patients witHatypical meningiomas SimpsoNgrade 4 and 5 witHa carbon ion boost in combination with postoperative photon radiotherapy: The MARCIE trial. BMC Cancer 2010;10:615
51. Cantu G, Bimbi G, Miceli R, Mariani L, Colombo S, Riccio S, et al. Lymph node metastases in malignant tumors of the paranasal sinuses: Prognostic value and treatment. Arch Otolaryngol Head Neck Surg 2008;134:170-7
52. Lloyd S, Yu J B, Wilson L D, Decker R H. Determinants and patterns of survivaLin adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy . Am J Clin Oncol 2011;34:76-81
53. Min R, Siyi L, Wenjun Y, O w A, Lizheng W, Minjun D, et al. Salivary gland adenoid cystic carcinoma with cervical lymph node metastasis: A preliminary study of 62 cases. Int J Oral Maxillofac Surg 2012;41:952-7
54. Lodge M, Pijls-Johannesma M, Stirk L, Munro AJ, De Ruysscher D, Jefferson T. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol 2007;83:110-22
55. Pommier P, Liebsch N J, Deschler D G, Lin D T, McIntyre JF, Barker FG, et al. Proton beam radiation therapy for skull base adenoid cystic carcinoma. Arch Otolaryngol Head Neck Surg 2006;132:1242-9
56. Huber P E, Debus J, Latz D, Zierhut D, Bischof M, Wannenmacher M, et al. Radiotherapy for advanced adenoid cystic carcinoma: Neutrons, photons or mixed beam? Radiother Oncol 2001;59:161-7
57. Schulz-Ertner D, Nikoghosyan A, Didinger B, Munter M, JakeLo, Karger CP, et al. Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer 2005;104:338-44
58. Combs SE, Konkel S, Thilmann C, Debus J, Schulz-Ertner D. Local high-dose radiotherapy and sparing of normal tissue using intensity-modulated radiotherapy (IMRT) for mucosal melanoma of the nasal cavity and paranasal sinuses. Strahlenther Onkol 2007;183:63-8
59. Hasegawa A, Koto M, Takagi R, et al. Carbon ion radiotherapy for head and neck tumors. Proceedings of the NIRS-ETOILE 2nd Joint Symposium on Carbon Ion Radiotherapy, 2011, Center ETOILE, Lyon, NIRS-M-243. 2011. [Abstract
60. Jingu K, Kishimoto R, Mizoe JE, Hasegawa A, Bessho H, Tsuji H, et al. Malignant mucosal melanoma treated with carbon ion radiotherapy with concurrent chemotherapy: Prognostic value of pretreatment apparent diffusion coefficient (ADC). Radiother Oncol 2011;98:68-73
61. Mizoe JE, Hasegawa A, Jingu K, Takagi R, BessyOh, Morikawa T, et al. Results of carbon ion radiotherapy for head and neck cancer. Radiother Oncol 2012;103:32-7
62. Mizoe J E, Tsujii H, Kamada T, Matsuoka Y, Tsuji H, Osaka Y, et al. Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;60:358-64
63. Yanagi T, Mizoe JE, Hasegawa A, Takagi R, Bessho H, Onda T, et al. Mucosal malignant melanoma of the head and neck treated by carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 2009;74:15-20
64. Jensen AD, Nikoghosyan A V, Windemuth-Kieselbach C, Debus J, Munter MW. Treatment of malignant sinonasal tumours with intensity-modulated radiotherapy (IMRT) and carbon ion boost (C12). BMC Cancer 2011;11:190
65. Jensen AD, Krauss J, Potthoff K, Desta A, Habl G, Mavtratzas A, et al. Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab anDintensity-modulated radiotherapy (IMRT) in combination witHa carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx-TPF-C-HIT. BMC Cancer 2011;11:182
66. Miyamoto T, Baba M, Sugane T, Nakajima M, Yashiro T, Kagei K, et al. Carbon ion radiotherapy for stage I nonsmall cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol 2007;2:916-26
67. Miyamoto T, Baba M, Yamamoto N, Koto M, Sugawara T, Yashiro T, et al. Curative treatment of stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Radiat Oncol Biol Phys 2007;67:750-8
68. Miyamoto T, Yamamoto N, Nishimura H, Koto M, Tsujii H, Mizoe JE, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 2003;66:127-40
69. Nishimura H, Miyamoto T, Yamamoto N, Koto M, Sugimura K, Tsujii H. Radiographic pulmonary and pleural changes after carbon ion irradiation. Int J Radiat Oncol Biol Phys 2003;55:861-6
70. Okada T, Kamada T, Tsuji H, Mizoe JE, Baba M, Kato S, et al. Carbon ion radiotherapy: ClinicaLexperiences at NationaLinstitute of Radiological Science (NIRS). J Radiat Res 2010;51:355-64
71. Sugane T, Baba M, Imai R, Nakajima M, Yamamoto N, Miyamoto T, et al. Carbon ion radiotherapy for elderly patients 80 years and older with stage I non-small cell lung cancer. Lung Cancer 2009;64:45-50
72. Yamamoto N. Carbon ion radiotherapy in a hypo-fractionate ion regimen for stage I non-small cell lung cancer. Proceedings of the Joint Symposium 2013 on Carbon Ion Radiotherapy, May 2-3, 2013, Rochester, MN, USA. 2013. [Abstract
73. Iwata H, Demizu Y, Fujii O, Terashima K, Mima M, Niwa Y, et al. Long-term outcome of proton therapy and carbon-ion therapy for large (T2a-T2bN0M0) non-smallcell lung cancer. J Thorac Oncol 2013;8:726-35
74. Yamamoto N, Nakajima M, Tsujii H, Kamada T. Carbon ion radiotherapy for oligo-recurrence in the lung. Pulm Med 2013;2013:219746
75. Akutsu Y, Yasuda S, Nagata M, Izumi Y, Okazumi S, Shimada H, et al. A phase I/II clinical triaLof preoperative short-course carbon-ion radiotherapy for patients with squamous cell carcinoma of the esophagus. J Surg Oncol 2012;105:750-5
76. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
77. Komatsu S, Fukumoto T, Demizu Y, Miyawaki D, Terashima K, Sasaki R, et al. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma . Cancer 2011;117:4890-904
78. Ling TC, Kang JI, Bush D A, Slater J D, Yang G Y. P roton therapy for hepatocellular carcinoma. Chin J Cancer Res 2012;24:361-7
79. Murayama S, Fuji H. [ Proton beam therapy at Shizuoka Cancer Center]. Gan To Kagaku Ryoho 2009;36:1806-12
80. KatOh, Tsujii H, Miyamoto T, Mizoe JE, Kamada T, Tsuji H, et al. Results of the fi rst prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys 2004;59:1468-76
81. Imada H, KatOh, Yasuda S, Yamada S, Yanagi T, Kishimoto R, et al. Comparison of effi cacy and toxicity of short-course carbon ion radiotherapy for hepatocellular carcinoma depending on their proximity to the porta hepatis. Radiother Oncol 2010;96:231-5
82. Habermehl D, Debus J, Ganten T, Ganten MK, Bauer J, Brecht IC, et al. Hypofractionated carbon ion therapy delivered with scanneDion beams for patients with hepatocellular carcinoma-feasibility and clinical response. Radiat Oncol 2013;8:59
83. Combs S E, Habermehl D, Ganten T, Schmidt J, Edler L, Burkholder I, et al. Phase I studYevaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: The PROMETHEUS-01 trial. BMC Cancer 2011;11:67
84. Quiros RM, Brown KM, Hoffman JP. N eoadjuvant therapy in pancreatic cancer. Cancer Invest 2007;25:267-73
85. White RR, Hurwitz HI, Morse MA, Lee C, Anscher MS, Paulson EK, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001;8:758-65
86. Evans D B, Rich TA, Byrd D R, Cleary K R, Connelly J H, Levin B, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992;127:1335-9
87. Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ, et al. A randomized phase 2 triaLof neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007;14:2088-96
88. Massucco P, Capussotti L, Magnino A, Sperti E, GattIm, Muratore A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: Analysis of perioperative outcome and survival. Ann Surg Oncol 2006;13:1201-8
89. Ammori JB, Colletti LM, ZalupskImM, Eckhauser FE, Greenson JK, Dimick J, et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previouslYunresectable adenocarcinoma of the pancreas. J Gastrointest Surg 2003;7:766-72
90. Hoffman J P, Weese J L, Solin L J, Engstrom P, Agarwal P, Barber LW, et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 1995;169:71-7
91. Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, FreedmaNg, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 2001;5:121-30
92. Yamada S, Shinoto M, Imada H, Yasuda S, Kamada T, Tsujii H. Carbon ion radiotherapy for patients with gastrointestinal cancer. PTCOG 49, Chiba, Japan. 2010
93. Yamada S. Carbon ion radiotherapy for patients with locally recurrent rectal cancer and pancreas cancer. Proceedings of the Joint Symposium 2013 on Carbon Ion Radiotherapy, May 2-3, 2013, Rochester, MN, USA. 2013. [Abstract
94. Yamada S, Shinoto M, Endo S. Carbon ion radiotherapy for patients with locally recurrent rectal cancer. Proceedings of the NIRS-ETOILE 2nd Joint Symposium on Carbon Ion Radiotherapy, 2011, Center ETOILE, Lyon, NIRS-M-243. 2011. [Abstract
95. Combs S E, Kieser M, Habermehl D, Weitz J, Jager D, Fossati P, et al. Phase I/II triaLevaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: The PANDORA-01 trial. BMC Cancer 2012;12:137
96. Zietman AL. The Titanic and the Iceberg: Prostate proton therapy and health care economics. J Clin Oncol 2007;25:3565-6. [Abstract
97. Tsuji H. Carbon ion radiotherapy for liver cancer and prostate cancer. Proceedings of the Joint Symposium 2013 on Carbon Iion Radiotherapy, May 2-3, 2013, Rochester, MN, USA. 2013. [Abstract
98. Shimazaki J, Tsuji H, Ishikawa H, Kamada T, Harada M, Akakura K, et al. Biochemical failure after carbon ion radiotherapy for prostate cancer. Anticancer Res 2012;32:3267-73
99. Jingu K, Tsujii H, Mizoe J E, Hasegawa A, Bessho H, Takagi R, et al. Carbon ion radiation therapy improves the prognosis of unresectable adult bone and soft-tissue sarcoma of the head and neck. Int J Radiat Oncol Biol Phys 2012;82:2125-31
100. Sugahara S, Kamada T, Imai R, Tsuji H, Kameda N, Okada T, et al. Carbon ion radiotherapy for localized primary sarcoma of the extremities: Results of a phase I/II trial. Radiother Oncol 2012;105:226-31
101. Fuchs B, Dickey ID, YaszemskImJ, Inwards CY, Sim FH. Operative management of sacral chordoma. J Bone Joint Surg Am 2005;87:2211-6
102. Ciernik IF, Niemierko A, Harmon DC, Kobayashi W, Chen YL, Yock TI, et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 2011;117:4522-30
103. Delaney T F, Liebsch NJ, Pedlow FX, Adams J, Dean S, Yeap BY, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 2009;74:732-9
104. Blattmann C, Oertel S, Schulz-Ertner D, Rieken S, Haufe S, Ewerbeck V, et al. Non-randomized therapy trial to determine the safety anDeffi cacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. BMC Cancer 2010;10:96
105. Bettega D, Calzolari P, Hessel P, Stucchi C G, Weyrather WK. Neoplastic transformation induced by carbon ions. Int J Radiat Oncol Biol Phys 2009;73:861-8
106. HalLe J. The impact of protons on the incidence of second malignancies in radiotherapy. Technol Cancer Res Treat 2007;6:31-4
107. HalLeJ. I ntensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006;65:1-7
108. Combs S E, Kessel K A, Herfarth K, Jensen A, Oertel S, Blattmann C, et al. Treatment of pediatric patients and young adults with particle therapy at the Heidelberg Ion Therapy Center (HIT): Establishment of workflow anDinitial clinical data. Radiat Oncol 2012;7:170
109. Bert C, Durante M. M otion in radiotherapy: Particle therapy. Phys Med Biol 2011;56:R113-44
110. Richter D, Schwarzkopf A, Trautmann J, Kramer M, Durante M, JakeLo, et al. Upgrade and benchmarking of a 4D treatment planning system for scanneDion beam therapy. Med Phys 2013;40:051722
111. RietzeLe, Bert C. R espiratory motion management in particle therapy. Med Phys 2010;37:449-60